X

Drug Profile

Imidazenil

Alternative Names: FGIN 2023; FID 02023; RO 231412

Latest Information Update: 10 Oct 2003

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Fidia Farmaceutici; Roche
Class Antiepileptic drugs; Antipsychotics; Anxiolytics; Benzodiazepines; Imidazoles; Neuroprotectants; Small molecules
Mechanism of Action GABA A receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Anxiety disorders; Cocaine-related disorders; Epilepsy

Most Recent Events

10 Oct 2003 Discontinued - Preclinical for Anxiety disorders in USA (unspecified route)
10 Oct 2003 Discontinued - Preclinical for Cocaine abuse in USA (unspecified route)
10 Oct 2003 Discontinued for Epilepsy in USA (unspecified route)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com